Main Ozempic Patents and Expiry Dates
Ozempic (semaglutide injection) is protected by multiple patents listed in the FDA's Orange Book, covering the compound, formulation, and delivery methods. The key composition-of-matter patent, US 8,129,343 (covering the semaglutide molecule), expires March 18, 2032, with pediatric exclusivity extending it to September 18, 2032.[1][2]
Novo Nordisk holds over 20 Orange Book patents for Ozempic, with expirations ranging from 2026 to 2034. Notable ones include:
- US 8,114,833 (injectable formulation): Expires December 17, 2031.[2]
- US 8,254,833 (GLP-1 agonists): Expires March 3, 2034.[2]
When Do Generics or Biosimilars Enter the Market?
No generics can launch until at least the final patent expires or is invalidated, likely post-2032. Multiple ANDA and 351(k) filings challenge these patents, with Novo Nordisk defending in ongoing Paragraph IV litigations against Mylan, Teva, and others. Trial dates are set for 2025-2026, potentially accelerating entry if patents are overturned.[1][2][3]
Why Multiple Patents and Extensions?
Novo uses patent thickets and regulatory exclusivities to extend protection. Ozempic received 5 years new chemical entity exclusivity (ended ~2023) plus 3 years for new indications. No NCE exclusivity blocks Paragraph IV challenges now.[2]
Patent Challenges and Litigation Status
- Hims & Hers, Viatris, and 15+ others filed ANDAs, triggering suits in Delaware federal court.[3]
- Novo settled with some (e.g., allowing entry no earlier than 2031 in certain cases), but most cases proceed to trial.[1]
- Check DrugPatentWatch for live updates on settlements or invalidations.[1]
How Does This Compare to Wegovy or Rybelsus?
Ozempic's patents overlap with Novo siblings:
| Drug | Key Patent Expiry | Notes |
|------------|-------------------|-------|
| Ozempic | 2032 (compound) | Injection for diabetes. |
| Wegovy | 2032 (same) | Higher-dose semaglutide for weight loss; separate formulation patents to 2035. |
| Rybelsus | 2032 (compound) | Oral version; additional patents to 2034.[2] |
Alternatives if Patents Hold
Patients face branded pricing (~$900/month) until expiry. Compounded semaglutide versions exist via 503B pharmacies amid shortages, but FDA warns of safety risks and deems them illegal post-shortage.[4] Tirzepatide (Mounjaro/Zepbound) patents expire later (2036+).[2]
Sources
[1]: DrugPatentWatch.com - Ozempic Patents
[2]: FDA Orange Book - Ozempic
[3]: Novo Nordisk Litigation Updates
[4]: FDA on Compounded Semaglutide